- In a new study, researchers reported that tirzepatide sold under the brand name Mounjaro was superior to semaglutide drugs such as Ozempic and Wegovy for diabetes management and weight loss.
- They reported that the side effects of tirzepatide included nausea, vomiting, and diarrhea.
- Experts point out that long-term weight loss requires a combination of diet, exercise, and behaviorial changes.
In a meta-analysis of 22 trials, researchers report that tirzepatide was superior to semaglutide for controlling blood sugar and weight loss.
The findings will be presented at the European Association for the Study of Diabetes annual meeting in Germany in early October.
The researchers have not yet published their study in a peer-reviewed journal.
The U.S. Food and Drug Administration (FDA) has
The FDA has
Of the 22 trials studied by researchers, two directly compared the drugs. The remaining trials compared one of the drugs to a placebo, basal insulin, or another GLP-1 RAs medication.
The researchers said that their analysis shows that tirzepatide is superior to semaglutide for diabetes management and weight loss.
Some of the results include:
- Tirzepatide 15 mg resulted in a loss of 12 more pounds than semaglutide 2 mg.
- Tirzepatide 10 mg resulted in a loss of nearly 8 more pounds than semaglutide 2 mg
- Tirzepatide 5 mg resulted in a loss of almost 4 more pounds than semaglutide 1 mg
When compared to a placebo, both drugs showed an increased risk of side effects, including gastrointestinal problems such as nausea, vomiting, and diarrhea. However, tirzepatide showed a greater increased risk.
“Both drugs work by activating glucagon-like peptide-1 (GLP-1) receptors in the body,” said Dr. Kathleen Dungan, a professor of medicine and the interim director in the Division of Endocrinology,…
Read the full article here